Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Glucose starvation and metformin have synergistic antitumor effects that are mediated through
the concomitant inhibition of glycolysis and mitochondrial oxidative phosphorylation. The
BREAKFAST trial will evaluate the antitumor activity of combining cyclic fasting-mimicking
diet (FMD), which reproduces the in vitro effects of glucose starvation, plus/minus metformin
with standard preperative anthracycline-taxane chemotherapy in patients with stage I-III TNBC
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collaborators:
European Institute of Oncology IFOM, The FIRC Institute of Molecular Oncology University of Milan